Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 11/20 | 0.55 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.44 |
| ▸ | NQO1 | P15559 | 1/20 | 0.43 |
| ▸ | TIPARP | Q7Z3E1 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | UBE2N | P61088 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29640845 | 1.00 | ROCK2 (0.55) | ROCK2ROCK1KDM4EHPGDPTBP1 | |
| SCHEMBL14816898 | 0.87 | ROCK2 (0.42) | ROCK2ROCK1KDM4EHPGDPTBP1 | |
| SCHEMBL29674712 | 0.83 | ROCK2 (0.58) | ROCK2ROCK1KDM4ETIPARPALDH1A1 | |
| SCHEMBL29908218 | 0.82 | ROCK2 (0.39) | ROCK2ROCK1KDM4EHPGDPTBP1 | |
| SCHEMBL16637499 | 0.82 | ROCK2 (0.57) | ROCK2ROCK1KDM4ETIPARPALDH1A1 | |
| SCHEMBL29628003 | 0.82 | HTR1A (0.48) | ROCK2ROCK1CTSS | |
| SCHEMBL29640451 | 0.81 | ROCK2 (0.44) | ROCK2ROCK1KDM4EHPGDPTBP1 | |
| SCHEMBL29627867 | 0.81 | CTSS (0.44) | ROCK2KDM4EHPGDALDH1A1POLB | |
| SCHEMBL20769723 | 0.78 | ROCK2 (0.56) | ROCK2ROCK1TIPARP | |
| SCHEMBL20770054 | 0.77 | ROCK2 (0.53) | ROCK2ROCK1TIPARP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542256-B2 | Vinylheterocycles as Rho-associated coiled-coil kinase (ROCK) inhibitors | ANGION BIOMEDICA CORP. (US) | 2023-01-03 | — | — | US | disclosed |
| US-11542256-B2 | Vinylheterocycles as Rho-associated coiled-coil kinase (ROCK) inhibitors | ANGION BIOMEDICA CORP. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220281841-A1 | ETHYNYLHETEROCYCLES AS RHO-ASSOCIATED COILED-COIL KINASE (ROCK) INHIBITORS | ANGION BIOMEDICA CORP. | 2022-09-08 | — | — | US | disclosed |
| EP-4003340-A2 | ETHYNYLHETEROCYCLES AS RHO-ASSOCIATED COILED-COIL KINASE (ROCK) INHIBITORS | Angion Biomedica Corp. (US) | 2022-06-01 | — | — | EP | disclosed |
| WO-2021016256-A2 | ETHYNYLHETEROCYCLES AS RHO-ASSOCIATED COILED-COIL KINASE (ROCK) INHIBITORS | ANGION BIOMEDICA CORP. (US) | 2021-01-28 | — | — | WO | disclosed |
| US-20200231576-A1 | VINYLHETEROCYCLES AS RHO-ASSOCIATED COILED-COIL KINASE (ROCK) INHIBITORS | ANGION BIOMEDICA CORP. | 2020-07-23 | — | — | US | disclosed |
| US-20200231576-A1 | VINYLHETEROCYCLES AS RHO-ASSOCIATED COILED-COIL KINASE (ROCK) INHIBITORS | ANGION BIOMEDICA CORP. | 2020-07-23 | — | — | US | disclosed |
| EP-3676262-A1 | VINYLHETEROCYCLES AS RHO-ASSOCIATED COILED-COIL KINASE (ROCK) INHIBITORS | Angion Biomedica Corp. (US) | 2020-07-08 | — | — | EP | disclosed |
| WO-2019046795-A1 | VINYLHETEROCYCLES AS RHO-ASSOCIATED COILED-COIL KINASE (ROCK) INHIBITORS | ANGION BIOMEDICA CORP. (US) | 2019-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281841-A1 | ETHYNYLHETEROCYCLES AS RHO-ASSOCIATED COILED-COIL KINASE (ROCK) INHIBITORS | ROCK1, ROCK2, CIT | ROCK2 2/4885ROCK1 1/4885KDM4E 2774/4885 |
| US-20200231576-A1 | VINYLHETEROCYCLES AS RHO-ASSOCIATED COILED-COIL KINASE (ROCK) INHIBITORS | ROCK1, ROCK2, RHOT2 | ROCK2 2/4885ROCK1 1/4885KDM4E 2076/4885 |
| US-11542256-B2 | Vinylheterocycles as Rho-associated coiled-coil kinase (ROCK) inhibitors | ROCK1, ROCK2, RHOT2 | ROCK2 2/4885ROCK1 1/4885KDM4E 2076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.